Cystinosis clinical trials
The registry lists 47 studies for Cystinosis across more than 10 countries. 15 are recruiting or about to start. 39 of them are mainly about Cystinosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-03.
Get an email when these change. Save the Cystinosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Amgen (5) · Cystinose Stiftung (3) · Hospices Civils de Lyon (3) · National Human Genome Research Institute (NHGRI) (2) · Novartis Pharmaceuticals (2) · Institut National de la Santé Et de la Recherche Médicale, France (2) · National Center for Research Resources (NCRR) (2) · National Eye Institute (NEI) (2)
What is being tested here
Drugs under test in Cystinosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Nov 2026Early Check: Expanded Screening in Newborns · RTI International
- Dec 2026Pilot Study of TTI-0102 in Cystinosis · Thiogenesis Therapeutics, Inc.
- Apr 2027European Cystinosis Cohort · Institut National de la Santé Et de la Recherche Médicale, France
Who these studies take
Of the 10 Cystinosis studies recruiting now, 4 (40%) set no upper age limit and 4 (40%) stop at 75 or younger. 10 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 8 (80%) | 8 (80%) |
| 18 | 8 (80%) | 8 (80%) |
| 30 | 7 (70%) | 7 (70%) |
| 40 | 6 (60%) | 6 (60%) |
| 50 | 6 (60%) | 6 (60%) |
| 65 | 6 (60%) | 6 (60%) |
| 75 | 6 (60%) | 6 (60%) |
| 85 | 6 (60%) | 6 (60%) |
Across all 47 studies, recruiting or not: 38% stop at 75 or younger and 36% at 65; 89% take children; 0% are for women only and 0% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 47 of 47. search them.
- European Cystinosis Cohort 2Not yet recruitingNCT076807511 country
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruitingNCT017931681 country
- DFT383 in Pediatric Participants With Nephropathic CystinosisRecruitingNCT06910813Phase 1/21 country
- Pilot Study of TTI-0102 in CystinosisNot yet recruitingNCT07837726Phase 2
- Use of Cysteamine in the Treatment of CystinosisRecruitingNCT003596841 country
- Cystinosis and Mitochondrial MetabolismRecruitingNCT07319091Not applicable1 country
- European Cystinosis CohortRecruitingNCT059010771 country
- Non-invasive Characterisation of Oral Carcinomas in Patients With Fanconi AnaemiaNot yet recruitingNCT07242261Not applicable
- Development of Health-related Quality of Life Instrument for Patients With CystinosisRecruitingNCT059596681 country
- A Long-Term Follow-Up Study of Participants With Cystinosis Who Previously Received CTNS-RD-04Enrolling by invitationNCT051468301 country
- RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)RecruitingNCT062134021 country
- National Registry of Rare Kidney DiseasesRecruitingNCT060658521 country
- Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same DonorRecruitingNCT05508009Phase 1/21 country
- Genetic Newborn Screening for Cystinosis and Primary HyperoxaluriaRecruitingNCT05843851Not applicable1 country
- Observational Study to Assess the Quality of Life in Nephropathic Cystinosis PatientsEnrolling by invitationNCT042460601 country
- CYSTEA-BONE Clinical StudyCompletedNCT039199814 countries
- PK and PD Study of NPI-001 and Cysteamine BitartrateCompletedNCT05994534Phase 1/21 country
- Stem Cell Gene Therapy for CystinosisCompletedNCT03897361Phase 1/21 country
- Early Check: Expanded Screening in NewbornsActive, not recruitingNCT036552231 country
- Clinical and Biological Study of Sub-pigmentation During Infantile CystinosisCompletedNCT00822250Not applicable1 country
- A Cohort of Patients With Cystinosis : Compliance to Cysteamine and Neurological ComplicationsCompletedNCT02012114Not applicable1 country
- Neuromuscular Characterisation in Late Adolescent and Adult Cystinosis PatientsCompletedNCT055457741 country
- Baby Detect : Genomic Newborn ScreeningCompletedNCT056874741 country
- Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With CystinosisCompletedNCT01744782Phase 32 countries
- Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in CystinosisCompletedNCT01733316Phase 36 countries
- Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)CompletedNCT01197378Phase 33 countries
- Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With CystinosisCompletedNCT00872729Phase 1/21 country
- Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With CystinosisCompletedNCT01000961Phase 33 countries
- The Effect of Exercise on Muscle Dysfunction in CystinosisCompletedNCT04071548Not applicable1 country
- Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2)CompletedNCT04125927Phase 35 countries
- Genetic Newborn Screening for Cystinosis and Spinal Muscular AtrophyCompletedNCT06027385Not applicable1 country
- A Phase 2 Study of ELX-02 in Patients With Nephropathic CystinosisTerminatedNCT04069260Phase 21 country
- Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of CystinosisWithdrawnNCT02124070Phase 1/2
- Kidney Transplantation in Patients With CystinosisCompletedNCT000745161 country
- The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control StudyCompletedNCT000719031 country
- Salivary Proteins in Disease and HealthCompletedNCT001002041 country
- A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe ToxicityCompletedNCT01044186Phase 23 countries
- Efficacy of Topical Cysteamine in Nephropathic CyctinosisCompletedNCT02766855Not applicable
- The Functional Consequences of the CTNS-deletion for the TRPV1-receptor in Cystinosis PatientsCompletedNCT02533076Early Phase 11 country
- Randomized Study of New Formulation Ophthalmic Cysteamine Hydrochloride for Corneal Cystine Accumulation in Patients With CystinosisCompletedNCT00010426Not applicable
- Cysteamine Eye Drops to Treat Corneal Crystals in CystinosisCompletedNCT00001213Phase 21 country
- Cure Cystinosis International RegistryStatus unknownNCT013278071 country
- Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™CompletedNCT01432561Not applicable1 country
- N Acetyl Cysteine for Cystinosis PatientsCompletedNCT01614431Phase 4
- New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in CystinosisCompletedNCT00001736Phase 11 country
- Establishment of a Database for Long-Term Monitoring of Patients With Nephropathic CystinosisCompletedNCT000043121 country
- Evaluation of Fanconi Syndrome and CystinosisCompletedNCT00004350